Further 3b/JG-98-derived benzothiazole rhodacyanines were described, culminating in the discovery of the bromothienyl analog 3f (JG-231), which showed high activity against MCF-7 (IC50 = 0.12 μM) and MDA-MB-231 breast cancer cells (IC50 = 0.25 μM), disruption of Bag3 interaction, amenable microsomal stability (half-life of more than 60 min), degradation of Akt and HuR in MCF-7 xenografts, amenable in vivo pharmacokinetics parameters and in vivo tumor growth inhibition of MDA-MB-231 xenografts at doses of 4 mg/kg (i.p.)[49]. The gene discussed is BAG3; the disease is neoplasm.